GlassScriptPhysician profile
Sayeda M Akbar
NPI 1710375860
$947.96
in general payments reported to CMS, 2019-2025
15 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $635 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $210.01 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Xeris Pharmaceuticals, INC. | $139.32 | 2024-2025 | Keveyis, Gvoke Hypopen |
| Novo Nordisk INC | $114.58 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $89.50 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $66.45 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.76 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.47 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $42.36 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $37.50 | 2024 | Voquezna |
| Abbott Laboratories | $37.27 | 2025 | Freestyle Libre 2 |
| Abbvie INC. | $31.12 | 2025 | |
| Daiichi Sankyo INC. | $21.08 | 2025 | Injectafer |
| Merck Sharp & Dohme LLC | $17.18 | 2024 | Gardasil 9, Gardasil, M-M-R II |
| Inspire Medical Systems, INC. | $16.56 | 2024 | Inspire |
| Amgen INC. | $15.80 | 2024 | Prolia, Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayeda Akbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.